Page last updated: 2024-11-06

nantradol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

nantradol: cannabinoid-related analgetic with greater potency than morphine in some tests; 4 stereoisomers are mentioned in the literature: (+)-2'(S),6(R),6a(S),9(S)10a(S) [CP-53,870-1]; (-)-2'(R),6(S),6a(R),9(R)10a(R) [CP-50,556-1]; (+)-2'(R),6(R),6a(S),9(S),10a(S); (-)-2'(S),6(S),6a(R),9(R)10a(R); RN given is from CA 1977-79 Index Guide; structure in first source; use STEREOISOMERS if levonantradol is used [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107822
SCHEMBL ID488911
MeSH IDM0084904

Synonyms (16)

Synonym
nantrodolum
6-methyl-3-(1-methyl-4-phenylbutoxy)-5,6,6a,7,8,9,10,10a-octahydro-1,9-phenanthridinediol acetate
l-nantradol
nantradol
72028-54-7
cas_71048-87-8
nsc_107822
nsc_51016
d-nantradol
cas_107822
bdbm84888
(+-)-5,6,6abeta,7,8,9alpha,10,10aalpha-octahydro-9beta-hydroxy-6beta-methyl-3-(1-methyl-4-phenylbutoxy)-1-phenanthridinyl acetat
SCHEMBL488911
l-nantradol; cp 50556-1
DTXSID10867161
9-hydroxy-6-methyl-3-[(5-phenylpentan-2-yl)oxy]-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl acetate

Research Excerpts

Dosage Studied

The current phase I trial was undertaken to determine: 1) the maximally tolerated dose; 2) the side effects at the different dosage levels; and 3) to evaluate the antiemetic efficacy of levonantradol in patients receiving emesis-producing chemotherapy.

ExcerptRelevanceReference
" The current phase I trial was undertaken to determine: 1) the maximally tolerated dose; 2) the side effects at the different dosage levels; and 3) to evaluate the antiemetic efficacy of levonantradol in patients receiving emesis-producing chemotherapy."( Phase 1 trial of levonantradol in chemotherapy-induced emesis.
Bordin, LA; Bosl, GJ; Clark, RA; Gralla, RJ; Kris, MG; Tyson, LB, 1985
)
0.27
" A biphasic log dose-response curve was observed for each of the cannabinoid drugs, such that reversal of the inhibition occurred at 3-10 microM."( Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes.
Fleming, RM; Howlett, AC, 1984
)
0.27
" Intramuscular levonantradol was prophylactically administered in random dosing to 20 subjects with a documented history of refractory emesis due to chemotherapy in advanced cancer."( Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis.
McAdams, J; Stambaugh, JE; Vreeland, F,
)
0.13
" By using a liquid chromatography assay with electrochemical detection, specific for both nantradol and desacetylnantradol, only desacetylnantradol is detected in plasma of rats and dogs dosed with nantradol."( Nantradol hydrochloride: pharmacokinetics and behavioral effects after acute and chronic treatment.
Johnson, MR; Mast, RW; McIlhenny, HM; Milne, GM, 1981
)
0.26
" Little or no evidence for drug accumulation and sex differences in plasma concentrations of desacetyllevonantradol is noted during chronic intramuscular dosing in laboratory animals."( Pharmacokinetics of levonantradol in laboratory animals and man.
Shepard, RM,
)
0.13
" Administration of the D(1) antagonist SCH23390 enhanced the effects of levonantradol, producing a leftward shift of the log dose-response curve."( Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity.
Conley, TJ; Howlett, AC; Meschler, JP, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-199030 (76.92)18.7374
1990's4 (10.26)18.2507
2000's3 (7.69)29.6817
2010's1 (2.56)24.3611
2020's1 (2.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (15.00%)5.53%
Reviews1 (1.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other50 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]